Memantine was better than placebo in Alzheimer disease already being treated with donepezil

Hirsch, Calvin H.
September 2004
ACP Journal Club;Sep/Oct2004, Vol. 141 Issue 2, p38
Academic Journal
This article investigates that treatment of patients with moderate to severe Alzheimer Disease (AD) with memantine was better than placebo. 404 patients ≥ 50 years of age (mean age 76 y, 65% women) with a diagnosis of probable AD, a mini-mental state examination score of 5 to 14, ongoing donepezil therapy for ≥ 6 months at a stable dose (5 to 10 mg/d) for≥ 3 months, a knowledgeable and reliable caregiver, ambulatory ability, and a stable medical condition were studied. Patients who received memantine had greater improvement than patients who received placebo in all cognitive, functional, and global outcome measures at 24 weeks.


Related Articles

  • Memantine for Treatment of Alzheimer's Disease. Wellbery, Caroline // American Family Physician;9/1/2004, Vol. 70 Issue 5, p963 

    Examines the efficacy of the use of memantine for the treatment of Alzheimer's disease. Adverse effect most often associated with placebo use; Beneficial effects of memantine use.

  • THE EFFECT OF THERAPEUTIC TOUCH ON BEHAVIORAL SYMPTOMS OF PERSONS WITH DEMENTIA. Woods, Diana Lynn; Craven, Ruth F.; Whitney, Joie // Alternative Therapies in Health & Medicine;Jan/Feb2005, Vol. 11 Issue 1, p66 

    Background Approximately 80% of nursing home residents who suffer from Alzheimer's disease and related dementia develop behavioral symptoms of dementia. Given the deleterious side effects of pharmacologic therapy in this population there is an urgent need for clinical trials of nonpharmacologic...

  • Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer's disease. Standridge, John B. // Evidence Based Mental Health;Nov2004, Vol. 7 Issue 4, p112 

    The article presents an answer to the clinical question related to the effect of donepezil in people with mild to moderate Alzheimer's disease. The superiority, typically in cognition, of donepezil and other cholinesterase inhibitors (ChEls) to placebo has been confirmed in a systematic review....

  • Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer's disease.  // Evidence Based Medicine;Feb2005, Vol. 10 Issue 1, p15 

    This article presents a clinical study which reports that long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer's disease. Patients in the donepezil and placebo groups did not differ for rates of institutionalisation at 1 year or 3 years....

  • Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomized double blind placebo controlled trial.  // BMJ: British Medical Journal (International Edition);4/16/2005, Vol. 330 Issue 7496, p874 

    Studies the role of Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease. Efforts to treat agitation in patients with Alzheimer's disease; Details of a placebo controlled trial.

  • Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimer's Disease. Aronson, Stephen; Van Baelen, Bart; Kavanagh, Shane; Schwalen, Susanne // Drugs & Aging;2009, Vol. 26 Issue 3, p231 

    Background: Galantamine (hydrobromide), a reversible acetylcholinesterase inhibitor and allosteric nicotinic receptor modulator, slows cognitive and functional decline in mild to moderate dementia of the Alzheimer's type. Although several drugs are indicated for mild to moderate Alzheimer's...

  • Ginkgo biloba has no effect on dementia progression.  // Australian Journal of Pharmacy;Aug2009, Vol. 90 Issue 1071, p70 

    The article reports that Ginkgo biloba (G biloba) has no effect on dementia progression. It mentions that in a conducted study, 523 people had developed dementia, 246 receiving placebo and 277 receiving G biloba, in which 92% of the volunteers have been classified as possible or probable...

  • Review: Atypical antipsychotic drugs increase risk for death in dementia.  // ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p36 

    This article presents a study which reveals that atypical antipsychotic drugs increase risk for death in dementia. 5 placebo controlled trials (RCT) with 16 comparisons met the selection criteria. 9 RCTs were unpublished. 87% of patients had Alzheimer disease. Patients were nursing home...

  • Nicergoline in the Treatment of Mild-to-Moderate Alzheimer's Disease: A European Multicentre Trial. Winblad, B.; Bonura, M.L.; Rossini, B.M.; Battaglia, A. // Clinical Drug Investigation;2001, Vol. 21 Issue 9, p621 

    Objective: To assess the long-term efficacy and tolerability of nicergoline 30mg twice daily in the treatment of mild-to-moderate Alzheimer's disease. Design: Multicentre, randomised, double-blind, placebo-controlled study of 6 months' duration. Setting: 33 investigational sites in five European...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics